Labcorp renews strategic partnership with Medidata

By The Science Advisory Board staff writers

April 6, 2022 -- Labcorp has extended its 14-year partnership with life sciences firm Medidata. The aim of the collaboration is to codevelop digital biomarkers and use them in decentralized clinical trials.

Apart from using Medidata technologies' Rave electronic data capture, Coder, and targeted source data verification, Labcorp will integrate the Medidata Clinical Cloud platform, including electronic clinical outcome assessment, randomization and trial supply management, and Imaging.

Financial agreements of the partnership were not disclosed.

If you like this content, please share it with a colleague!

Related Reading

GeneCentric Therapeutics teams up with Labcorp
GeneCentric Therapeutics has formed a strategic partnership with Labcorp to develop and commercialize RNA-based gene signatures for oncology diagnostics.

Medidata lands Labcorp as new client
Labcorp Drug Development has chosen Medidata's Sensor Cloud platform to expand its decentralized clinical trial capabilities.

Labcorp, CCORN collaborate to understand cancer disparities
Labcorp is collaborating with the Community Clinical Oncology Research Network (CCORN) to better understand the impact of disparities in precision medicine...

zPredicta partners with LabCorp for cell cultures R&D
LabCorp and zPredicta have partnered to promote the use of 3D cell cultures for drug research and development.

LabCorp adopts Thermo Fisher NGS for companion diagnostics
LabCorp announced on January 14 that it will adopt Thermo Fisher Scientific's Ion Torrent Genexus next-generation sequencing (NGS) system and Oncomine...